5-fluoro-2',3',5',6'-tetrahydrospiro[fluorene-9,4'-pyran]-2-carboaldehyde | 863600-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 5-fluoro-2',3',5',6'-tetrahydrospiro[fluorene-9,4'-pyran]-2-carboaldehyde
• 英文别名: 5-Fluorospiro[fluorene-9,4'-oxane]-2-carbaldehyde
• CAS: 863600-56-0
• 化学式: C₁₈H₁₅FO₂
• 分子量: 282.314
• InChiKey: LAOFGFSCTWSESU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoro-2',3',5',6'-tetrahydrospiro[fluorene-9,4'-pyran]-2-carboaldehyde 在 sodium dihydrogenphosphate 、 2-甲基-2-丁烯 、 sodium perchlorate 、 水 作用下， 以 乙腈 、 叔丁醇 为溶剂， 生成 5-fluoro-2',3',5',6'-tetrahydrospiro[fluorene-9,4'-pyran]-2-carboxylic acid
  参考文献：
  名称：

  EP1728784

  摘要：

  公开号：
• 作为产物：
  描述：

  在 水 、 silver nitrate 作用下， 以 丙酮 为溶剂， 生成 5-fluoro-2',3',5',6'-tetrahydrospiro[fluorene-9,4'-pyran]-2-carboaldehyde
  参考文献：
  名称：

  EP1852129

  摘要：

  公开号：

文献信息

• Flourene Derivative
  申请人：Yamada Hiroyoshi

  公开号：US20080200551A1

  公开（公告）日：2008-08-21

  This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT 2B receptor and 5-HT 7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT 2B receptor and 5-HT 7 receptor, this is useful as a prophylactic antimigraine agent having high safety and excellent effect.

  这项发明涉及一种新颖的芴衍生物，其具有特征结构，其中脲基或类似的官能团通过羰基与芴结构连接，或其盐。该化合物具有优点，即它对5-HT2B受体和5-HT7受体等血清素受体亚型具有高亲和力，并与仅具有5-HT2B受体和5-HT7受体拮抗活性之一的传统化合物相比，显示出出色的药理效应，因此可用作具有高安全性和出色效果的预防性抗偏头痛剂。
• Medicament For Irritable Bowel Syndrome
  申请人：Akuzawa Shinobu

  公开号：US20080171788A1

  公开（公告）日：2008-07-17

  The invention relates to a medicament for IBS, which comprises a dual antagonist for 5-HT 2B and 5-HT 7 receptors having selective binding affinities for 5-HT 2B and 5-HT 7 receptors. The pharmaceutical composition of the invention is useful as a drug which is excellent in the therapeutic effect on IBS and shows lessened side effects occurring in the existing remedies for IBS, because it showed good pharmacological actions in comparison with the case of independently using a 5-HT 2B receptor antagonist having selective binding affinity for 5-HT 2B receptor or a 5-HT 7 receptor antagonist having selective binding affinity for 5-HT 7 receptor.

  本发明涉及一种治疗肠易激综合征（IBS）的药物，包括一种对5-HT2B和5-HT7受体具有选择性结合亲和力的双重拮抗剂。本发明的制药组合物作为一种药物对IBS具有优异的治疗效果，并且与现有的IBS治疗药物相比，具有减少副作用的优点，因为与单独使用具有选择性结合亲和力的5-HT2B受体拮抗剂或5-HT7受体拮抗剂相比，它表现出良好的药理作用。
• PREVENTIVES FOR MIGRAINE
  申请人：Astellas Pharma Inc.

  公开号：EP1716867A1

  公开（公告）日：2006-11-02

  The present invention relates to prophylactic antimigraine agents comprising as an active ingredient a dual antagonist for the 5-HT2B and 5-HT7 receptors, the antagonist having a binding affinity selective for the 5-HT2B and 5-HT7 receptors. Since these prophylactic antimigraine agents show an excellent pharmacological effect in comparison with the cases in which a 5-HT2B receptor antagonist having a selective binding affinity to the 5-HT2B receptor or a 5-HT7 receptor antagonist having a selective binding affinity to the 5-HT7 receptor is used alone, they are useful as drugs which are excellent in prophylaxis of migraine and in which the side effects found in the existing prophylactic antimigraine agents are reduced.

  本发明涉及预防性抗偏头痛制剂，其活性成分包括 5-HT2B 和 5-HT7 受体双重拮抗剂，该拮抗剂对 5-HT2B 和 5-HT7 受体具有选择性结合亲和力。 与单独使用对 5-HT2B 受体具有选择性结合亲和力的 5-HT2B 受体拮抗剂或对 5-HT7 受体具有选择性结合亲和力的 5-HT7 受体拮抗剂的情况相比，这些预防性抗偏头痛药剂显示出卓越的药理作用，因此，它们可作为预防偏头痛的良药，并可减少现有预防性抗偏头痛药剂的副作用。
• FLUORENE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1728784A1

  公开（公告）日：2006-12-06

  This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an advantage in that it has high affinity for serotonin receptor subtypes, particularly for 5-HT2B receptor and 5-HT7 receptor, and shows excellent pharmacological effects in comparison with the conventional compounds which have only one of the antagonistic activities of 5-HT2B receptor and 5-HT7 receptor, this is useful as a prophylactic antimigraine agent having high safety and excellent effect.

  本发明涉及一种新型芴衍生物，其特征结构是胍基或类似官能团通过羰基与芴结构相连，或其盐类。 本发明化合物的优点在于它对血清素受体亚型，特别是对 5-HT2B 受体和 5-HT7 受体具有高亲和力，与传统化合物相比，它只对 5-HT2B 受体和 5-HT7 受体中的一种具有拮抗活性，显示出优异的药理作用，可用作预防性抗偏头痛药，安全性高，效果优异。
• REMEDY FOR IRRITABLE BOWEL SYNDROME
  申请人：Astellas Pharma Inc.

  公开号：EP1852129A1

  公开（公告）日：2007-11-07

  The invention relates to a medicament for IBS, which comprises a dual antagonist for 5-HT2B and 5-HT7 receptors having selective binding affinities for 5-HT2B and 5-HT7 receptors. The pharmaceutical composition of the invention is useful as a drug which is excellent in the therapeutic effect on IBS and shows lessened side effects occurring in the existing remedies for IBS, because it showed good pharmacological actions in comparison with the case of independently using a 5-HT2B receptor antagonist having selective binding affinity for 5-HT2B receptor or a 5-HT7 receptor antagonist having selective binding affinity for 5-HT7 receptor.

  本发明涉及一种治疗肠易激综合征的药物，它包括一种对 5-HT2B 和 5-HT7 受体具有选择性结合亲和力的 5-HT2B 和 5-HT7 受体双重拮抗剂。 与单独使用对 5-HT2B 受体具有选择性结合亲和力的 5-HT2B 受体拮抗剂或对 5-HT7 受体具有选择性结合亲和力的 5-HT7 受体拮抗剂的情况相比，本发明的药物组合物显示出良好的药理作用，因此可作为一种对肠易激综合征具有良好治疗效果的药物，并减少现有治疗肠易激综合征的药物所产生的副作用。